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Abstract 
The new millennium has brought with it a surge of research in the field of epigenetics.  
This has included advances in our understanding of stem cell characteristics and 
mechanisms of commitment to cell lineages prior to differentiation.  The nature of stem 
cells is similar to that of malignant cells in that they have unlimited self-renewal and 
protection from apoptosis, leading researchers to suspect that stem cells are the target 
of oncogenesis.  This review will explore the idea of how epigenetic control of gene 
expression may contribute to mechanisms controlling differentiation of myeloid 
progenitor cells and its importance to our understanding of myelogenous leukemias.  
Recent developments in epigenetic research pertaining to differentiation of myeloid 
progenitor cells and hematopoietic stem cells are presented including aspects of cellular 
memory, general myelopoiesis, change in gene expression patterns, signal transduction, 
and the influence of the microenvironment. 
 
Abbreviations 
AML  = acute myelogenous leukemia 
CLP  = common lymphoid progenitor 
CML  = chronic myelogenous leukemia 
CMP  = common myeloid progenitor 
DNMT  = DNA methyltransferase 
EMP  = erythroid-megakaryocyte progenitor 
GMP  = granulocyte-monocyte progenitor 
HSC  = hematopoietic stem cell 
MDS  = myelodysplastic syndrome 
MP-B  = myeloid progenitor for basophils 
MP-E  = myeloid progenitor for erythrocytes 
MP-Es  = myeloid progenitor for eosinophils 
MP-M  = myeloid progenitor for monocytes 
MP-Meg = myeloid progenitor for megakaryocytes  
MP-N  = myeloid progenitor for neutrophils 
MPD  = myeloproliferative disease 
MPC  = myeloid progenitor cell compartment 
Pc-G  = polycomb group 
SFRPs  = secreted frizzled-related proteins 
Trx-G  = trithorax group 
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Figure 1: Epigenetics in 
Myelopoiesis.  The processes that 
are the targets of epigenetic 
regulation are summarized.  The 
HSC exhibits gene expression 
promiscuity that may be the result of 
the loss of gene silencing.  
Differentiation of the HSC into the 
myeloid lineages is influenced 
largely by the microenvironment 
through signal transduction 
pathways such as Wnt, as well as 
autocrinic signaling through the IL-6.  
During the process of differentiation, 
Hox gene expression patterns must 
be maintained in the form of cellular 
memory by the Pc-G and Trx-G 
genes. 
 
Myelopoiesis is a system of differentiation starting with the pluripotent hematopoietic 
stem cell (HSC) and proceeding to progressively determined progenitor cell types until 
terminating in the mature cell types of the myeloid lineages.  This review will examine 
the role of epigenetic gene regulation on myelopoiesis and its relevance to our 
understanding of leukemogenesis.  Epigenetics is defined as changes in gene 
expression that are not sequence based, which can be propagated through mitosis or 
meiosis.  The most extensively studied forms of epigenetic gene control are histone 
modification and DNA methylation.  Many aspects of epigenetic control of differentiation 
have been characterized in Drosophila.  The connection of epigenetics to cancer has 
lately become one of the most extensively studied aspects of oncogenesis.  The concept 
of stem cells being the target of oncogenesis in leukemias has been reviewed 
recently[1], as well as the general concepts of epigenetics and cancer[2].  This review 
will explore the idea of how epigenetic control of gene expression may contribute to 
mechanisms controlling differentiation in this milieu of progenitor cells, known as the 
myeloid progenitor cell compartment (MPC), and its importance to our comprehension of 
myelogenous leukemias (Fig. (1)).  
 
 
Epigenetics and differentiation 
The trithorax group (Trx-G) and polycomb group (Pc-G) genes were initially 
characterized in Drosophila and yeast as regulators of transcription through chromatin 
remodeling, an epigenetic mechanism.  The Trx-G genes maintain stable transcription of 
genes, while the Pc-G genes are responsible for gene silencing.  These two gene 
families act antagonistically to control the expression of the homeobox transcription 
factor gene family by providing cellular memory of cell fate decisions.  The homeobox 
gene family (or Hox gene family in mammalian systems) is responsible for making cell 
fate decisions.  Since the homeobox genes are under control of the Trx-G and Pc-G 
genes, mutations in these two gene families result in loss of regulated expression of the 
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homeobox genes and aberrations in cell lineage decisions.  Identification of direct 
targets of Pc-G gene complexes has been thwarted by the lack of sequence specific 
DNA elements in mammalian systems, though they have been identified in 
Drosophila[3].  A recent discovery in this field through the use of clever microarray 
experiments is several direct targets of the histone modifying Pc-G complexes[4]. 
Hox genes have been implicated in leukemic transformation since 1988, when the 
WEHI-3B leukemic cell line was found to contain proviral integrations resulting in 
transcriptional activation of Hoxb8 and Interleukin-3[5].  Evidence has continued to 
accumulate implicating other Hox genes in leukemia, including myeloid ecotropic 
integration site 1 (Meis1)[6,7].  This gene has recently been found to be inactivated in 
acute myelogenous leukemia (AML) by hypermethylation[8] and its cofactors in leukemic 
transformation, HoxA7 and HoxA9, have been found to be expressed in HSCs[9].   
Myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), and AML are 
related hematopoietic malignancies in that MDS and MPD often progress to AML.  AML 
is characterized by loss of regulation of cell lineage decisions, resulting in the over-
proliferation of immature myeloid cells.  The impact of epigenetics in leukemia is seen in 
multiple significant examples.  These epigenetic effects include increased methylation of 
the Pa promoter of Abl seen in advanced phases of chronic myelogenous leukemia 
(CML)[10,11], in addition to methylation of Bcr in lymphoid blast crisis[12].  
Hypermethylation of p15, an inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6, is 
also associated with CML transformation[13].  The importance of p15 is seen in disease 
progression from MDS to AML, where p15 is targeted for hypermethylation in 78% of 
samples at the time of leukemic transformation[14].  Also, increased expression levels of 
the DNA methyltransferase (DNMT) genes DNMT1, DNMT3A, and DNMT3B correlate 
with blast phase CML[15].  Epigenetics may be a significantly more important 
mechanism in AML progression than in other cancers, because chromosomal instability 
does not seem to be predominant (57.6% de novo AML patients have normal 
cytogenetics)[16].  Hypermethylation as a mechanism of gene regulation is seen 
frequently in AML, and may be more frequent in young adults where AML is the most 
common form of leukemia[17]. 
An overview of myelopoiesis 
Hematopoiesis is a robust system of cell production capable of replacing about five 
hundred billion blood cells each day in the human body[18].  The production of these 
cells occurs largely in the bone marrow.  The HSC is a rare cell type, with a frequency of 
10-3 to 10-4 in bone marrow.  In order to provide the large number of cells needed on a 
regular basis, an exponential amplification system is employed.  In this system, the 
largely quiescent HSC[19-21] produces progenitor cells with increased proliferative 
capacity, but reduced differentiation potential (Fig. (2)).  Maintenance of the HSC pool 
and production of progenitors occurs through asymmetric cell division[22], where one 
daughter cell retains its stem cell nature and the other enters a transient amplifying 
population.  This is a conserved mechanism in adult tissues with a high turnover rate 
such as blood, intestinal epithelium, and skin.  These progenitor cells are highly prolific 
and are responsible for providing for the daily need of new blood cells.  The frequency of 
these progenitor cells in bone marrow is 5 to 10 fold greater than that of the HSC. 
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Figure 2: Schematic of Myelopoiesis.  The hematopoietic stem cell (HSC) is the most 
pluripotent stem cell in hematopoiesis, from which all other hematopoietic cells are derived.  
HSCs can be grouped into short-term and long-term HSCs (not shown), which differ in that 
short-term HSCs no longer have unlimited self-renewal.  Once self-renewal is lost it is not 
regained in subsequent progenitor differentiation.  The HSC can differentiate into the common 
lymphoid progenitor (CLP) or common myeloid progenitor (CMP) that are responsible for 
generating their respective parts of the hematopoietic system.  The myeloid progenitor cell 
compartment (shown as the textured area in the blow up) consists of the CMP; oligopotent 
progenitors, the erythroid-megakaryocyte progenitor (EMP) and granulocyte-monocyte 
progenitor (GMP); and committed myeloid progenitors.  There are six major lineages of 
myeloid cells produced during myelopoiesis.  Each lineage is produced from a corresponding 
committed myeloid progenitor shown in the figure above: megakaryocyte (MP-Meg), 
erythrocyte (MP-E), basophil (MP-B), eosinophil (MP-Es), monocyte (MP-M), and neutrophil 
(MP-N).   
 
The current understanding of this system indicates that several classes of progenitor 
cells are present that vary in differentiation potential.  The common progenitor cells of 
the lymphoid (CLP) and myeloid lineages (CMP) are produced by the HSC.  These 
common progenitors are capable of producing all of the cells of their respective lineages.  
These common progenitors lose differentiation potential as they mature.  This eventually 
results in highly prolific progenitor cells that have a differentiation potential restricted to a 
single cell type.  These committed myeloid progenitors (committed MPs, Fig. (2)) have 
lost the self-renewal capacity stem cells possess.  The committed MPs will proliferate, 
mobilize from the marrow, and differentiate to mount the cellular immune response of 
terminally differentiated myeloid cells in the periphery[23].  The myeloid differentiation 
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specific cytokine IL-6[24,25] has been found to induce the expression of DNA 
methyltransferase 1 (DNMT-1)[26] , which has been found to occur through the 
transcriptional activation of FLI-1, a transcription factor that up-regulates DNMT-1[27].  
Lately, cDNA microarray analysis of the KAS-6/1 multiple myeloma cell line treated with 
the demethylating drug, zebularine, showed methylation of several genes contributing to 
growth and survival[28].  IL-6 treatment allowed cells to recover their viability and 
methylation status of apoptosis and proliferation related genes after exposure to 
zebularine. 
Gene expression promiscuity of the HSC 
The HSC and various progenitors can be isolated by flow cytometry using appropriate 
cell surface markers[1], allowing for the molecular characterization of these cell types.  
This approach has had some success in determining the nature of the genomic events 
associated with stem cell differentiation and the genes responsible.  Genomic 
technologies have helped characterize the nature of stem cell differentiation.  HSCs are 
promiscuous in their expression profiles in that they exhibit expression of a large number 
of genes when compared to progenitor cells of the lymphoid and myeloid lineages.  
When comparing the HSC gene expression profile with that of the CMP and CLP it was 
found that the HSC had 8 fold more differentially expressed transcripts than the CLP and 
21 fold more than the CMP[9].  As the progenitors continue to differentiate into more 
committed cell types, the levels of differentially expressed transcripts rise but still remain 
only one-quarter that of the HSC.  Thus, the HSC maintains a promiscuous transcription 
profile that is reduced significantly when it moves from the quiescent HSC to the prolific 
progenitor cell pool.  Experimental data suggests that this promiscuous gene expression 
profile includes low level transcription of many genes that are lineage specific[29,30].  
This may prime the HSC for differentiation into many lineages, one of which is selected 
in response to environmental stimuli.   
Examining this promiscuity from an epigenetic viewpoint suggests that large scale 
genomic silencing events occur after a lineage decision by the HSC.  Gene silencing is 
known to be an important aspect of cellular identity and lineage choice[31-33].  The 
concept that genome-wide increases in methylation during early differentiation and 
organogenesis may restrain the lineage choices of maturing cells during late 
development has been postulated[34].  Recently, investigators have provided evidence 
that chromatin remodeling events are preliminary to relatively late occurring enhancer 
complex assembly and high-level gene expression in hematopoietic cell differentiation in 
mouse bone marrow[35].  These investigations concentrated on the c-fms (Csf1r), the 
macrophage colony-stimulating factor receptor, and chicken lysozyme locus (clys) genes 
in macrophage development.  Other experiments investigating c-fms found it to be 
selectively silenced in all hematopoietic cells except the HSC and those of the 
macrophage lineage[36].  This silencing may be triggered by factors asymmetrically 
allocated during cell division or by the signal transduction events that trigger the 
differentiation.  Once restrictive chromatin is established through histone modification or 
DNA methylation, active measures must be invoked to remove these modifications since 
they are relatively stable, even through cell division[37].   
It remains to be seen whether the transcription promiscuity of the genome as a whole is 
the result of an overall reduced level of chromatin silencing, or maintained transcriptional 
activity in the presence of chromatin silencing.  A recent report provides evidence that 
reduced levels of DNA methylation block differentiation and are associated with 
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hyperacetylation of histones, supporting the idea that stem cells maintain open 
chromatin conformations on a genomic scale[38].  If chromatin silencing is still largely in 
effect, low level transcription may be necessary to prime the HSC for differentiation 
down multiple lineages by preventing restrictive chromatin conformations that will inhibit 
transcription of genes necessary for differentiation.  It may be that stem cells prevent 
these closed conformations in chromatin through maintenance of transcription or through 
a general inhibition of factors involved in silencing.  It will be interesting to determine if 
one of the defining characteristics of stem cells is a unique condition in the epigenetic 
regulatory machinery. 
Signal transduction in myelopoiesis 
In addition to lineage specific genes, the HSC and progenitor cells express many genes 
involved in signal transduction pathways[9].  Four signal transduction pathways are 
implicated in general stem cell biology including the Wnt, Notch, Bmp, and Hedgehog 
pathways.  Evidence now exists showing that epigenetic control, of at least some of 
these pathways, is an important aspect of their regulation in oncogenesis.  There is a 
substantial body of data linking the hedgehog pathway to stem cells in fish, chickens and 
Drosophila [39-42].  Bone morphogenetic proteins (BMPs) belong to the transforming 
growth factor-beta super-family.  The BMP signaling pathway has been found to be 
epigenetically activated by DNA demethylation in prostate cancer[43].  The Wnt and 
Notch signal transduction families have been shown to be extremely important in HSC 
and hematopoietic progenitor cell fate decisions[44-48].  Evidence exists that shows 
both of these signaling pathways are important in promoting self-renewal in HSCs and 
progenitors[48-51].  However, the involvement of the Wnt pathway in hematopoiesis is 
still under debate as inactivation of β-catenin, a downstream cytosolic/nuclear factor in 
the Wnt pathway, in mice was recently found to have no effect on hematopoiesis[52].  
There also is evidence suggesting epigenetic control in the Notch pathway but no direct 
links have been found.  The prospect of cellular memory in the case of blood vessel 
formation suggests a role for epigenetic control mechanisms in cell fate decisions 
mediated by the Notch pathway[53].  The Wnt pathway is an interesting story, and so far 
has shown the most direct connection with epigenetic modification, stem cells, and 
cancer. 
In addition to the its role in stem cell maintenance, the Wnt pathway has been implicated 
in cellular proliferation, polarity, and fate decisions[54].  Not surprisingly, the WNT 
pathway has been implicated in colorectal and skin cancers[55-57].  Furthermore, it has 
been shown that deregulated WNT pathway signaling is an early progression event in 
90% of colorectal cancers[58].  My colleagues and I have found that the Wnt pathway 
can be upregulated in Drosophila in response to perturbations in epigenetic 
regulators[59], indicating a role of epigenetic gene control in this pathway.  In these 
studies, mutations in Trx-G genes induced up regulation of the Wnt pathway.  Since Trx-
G genes are responsible for maintenance of active transcription, a mutation in Trx-G 
genes will result in loss of transcription.  These results indicate a gene under epigenetic 
control involved in repression of the Wnt pathway, since loss of the gene product 
upregulates the WNT pathway.  A possible explanation of these results has surfaced 
recently with the discovery that the secreted frizzled-related proteins (SFRPs)[60].  
These proteins have been implicated in colorectal cancers and shown to be negatively 
regulated by DNA methylation early in these cancers[61,62].  The SFRPs negatively 
regulate the Wnt pathway by sequestering the ligand.  The importance of these results to 
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stem cell biology is that they suggest that epigenetic control may be a mechanism of 
Wnt pathway regulation in normal physiology. 
Microenvironmental effects on myelopoiesis 
It is becoming increasingly apparent that the cellular microenvironment is drastically 
different in cancerous tissue and normal tissue.  This was elegantly shown in SAGE 
(serial analysis of gene expression) studies of malignant breast tissue and normal breast 
tissue[63].  The researchers found that even early in breast tumor progression the 
surrounding tissue had a dramatically different gene expression profile than normal 
tissue.  When combined with a recent finding that mammary tumors only formed when 
the stromal network was treated with a carcinogen[64], regardless of whether the 
injected endothelial cells were treated with carcinogen in vitro, indicate that the 
surrounding cells of a tumor greatly impact its progression to full malignancy.  There is 
corroborating evidence for this supposition in MDS, where marrow stromal layers from 
patients with MDS had an increased ability relative to normal marrow stroma to augment 
apoptosis of the GM-CSF and IL-3-dependent cell line F-36P[65].   
Since SFRPs are secreted molecules, they are a potential mechanism under epigenetic 
control to allow the microenvironment of the bone marrow to influence HSC and 
progenitor cell homeostasis.  The microenvironment of bone marrow is determined by 
stromal cells present in the bone marrow.  These stromal cells are a diverse network of 
cell types including fibroblasts, adipocytes, endothelial cells, and macrophages.  
Additionally, osteoblasts may serve a role in HSC maintenance and progenitor cell 
maturation[66].  Both osteoblast and stromal cell lines have been found to express 
SFRP1[67].   
The effect of microenvironmental influences of bone marrow stroma could be a factor in 
the idea of “field leukemogenic effect” postulated recently[68].  This idea is an adaptation 
of field cancerization in solid tumors developed in the 1950s[69].  Field cancerization is 
defined as diffuse injury to an organ resulting from long-term exposure to carcinogens.  
This results in a variety of mutations to different cells in the organ, which can be 
propagated through the tissue as the cells divide resulting in large areas of cells or 
“fields” that contain the same mutation.  In field leukemogenic effect there are several 
abnormal hematopoietic cell clones that produce different types of aberrant cells as the 
result of a generalized insult to bone marrow.  One of these clones predominates, while 
the others remain present but below detectable levels.  It is possible that field effects 
may include regions of stromal cells that have been altered to be supportive for 
premalignant cells.  This is important to treatment strategies in hematopoietic 
malignancies because the secondary clones can become more pronounced once the 
primary clone has been reduced by treatment, resulting in new malignancies.  The idea 
of field leukemogenic effect can be extrapolated to include epigenetic modifications to 
the genome that can affect both the microenvironment and stem/progenitor cells of bone 
marrow. 
Conclusion 
New techniques are allowing studies of epigenetic gene regulation on the genomic 
scale.  These will continue to provide exciting new results that will increase our 
understanding of this regulatory mechanism in differentiation and its impact on cellular 
transformation.  Currently, the five-year survival rate for AML is the lowest of the 
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leukemias at 21%, necessitating urgency in new chemotherapy.  Because epigenetic 
gene regulation correlates with early malignancies and progression, epigenetic 
etiological studies hold the promise of producing powerful diagnostic tools.  Insights into 
new treatment and diagnostic modalities in AML, MDS, and MPS will result from our 
discoveries in epigenetic gene regulation of myelogenesis. 
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